Contineum Therapeutics Reports Positive Data from PIPE-791 Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 30 2026
0mins
Contineum Therapeutics reported positive topline data from its exploratory Phase 1b trial of PIPE-791, a potentially best-in-class selective antagonist of the lysophosphatidic acid 1 (LPA1) receptor, for the non-opioid treatment of chronic osteoarthritis pain or chronic low back pain. The randomized, double-blind, placebo-controlled, 4-week, crossover trial enrolled 43 patients (23 COAP and 20 CLBP). The trial design incorporated a washout period for patients prior to the first 4-week treatment period (TP1), after which patients crossed over immediately into a second 4-week treatment period (TP2) without an intervening PIPE-791 washout. PIPE-791 was administered orally at 10mg once-daily.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CTNM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CTNM
Wall Street analysts forecast CTNM stock price to rise
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 14.370
Low
14.00
Averages
18.60
High
22.00
Current: 14.370
Low
14.00
Averages
18.60
High
22.00
About CTNM
Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications with significant unmet need. It is advancing a pipeline of internally developed programs with multiple drug candidates in clinical trials. Its lead asset, PIPE-791, is a novel, brain-penetrant, small-molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF), progressive multiple sclerosis (PrMS), and chronic pain. Its second drug candidate, PIPE-307, is a novel, small-molecule selective inhibitor of the muscarinic type 1 receptor (M1R), in development for depression and relapse-remitting multiple sclerosis (RRMS). The Company is also conducting preclinical and discovery-phase experiments targeting other NI&I indications where its internally discovered molecules may have therapeutic potential.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Contineum Therapeutics Q1 Financial Results
- Financial Performance: Contineum Therapeutics reported a Q1 GAAP EPS of -$0.39, indicating challenges in profitability that may affect investor confidence and market perception.
- Cash Reserves: As of March 31, 2026, the company held $246.3 million in cash, cash equivalents, and marketable securities, suggesting a degree of financial flexibility in the short term.
- Funding Outlook: Contineum believes its cash resources are sufficient to fund planned operations through mid-2029, reflecting confidence in future growth while highlighting current profitability concerns.
- Market Considerations: Despite the current financial struggles, Contineum must remain vigilant regarding market trends to ensure its long-term strategy can adapt to the evolving industry landscape.
See More
Contineum Therapeutics Reports Positive Phase 1b Trial Results for PIPE-791
- Trial Success: Contineum Therapeutics' PIPE-791 achieved its primary endpoint in the Phase 1b trial for chronic osteoarthritis pain and chronic low back pain, demonstrating favorable safety and tolerability, indicating its potential in non-opioid pain management.
- Trial Design Details: The study was a randomized, double-blind, placebo-controlled, 4-week crossover trial enrolling 43 patients, with 23 suffering from chronic osteoarthritis and 20 from chronic low back pain, using a daily oral dose of 10mg, ensuring the reliability of the results.
- Efficacy Assessment Results: Results indicated that patients treated with PIPE-791 showed significant improvements in pain intensity from baseline, with greater reductions compared to the placebo group, supporting further evaluation of the drug's application in chronic pain treatment.
- Positive Stock Reaction: Following the trial results announcement, CTNM's stock rose 6.48% to close at $12.82, and further increased by 9.20% in after-hours trading to $14, reflecting market optimism regarding the drug's prospects.
See More
Contineum Therapeutics Reports Q4 Earnings and Public Offering
- Earnings Report: Contineum Therapeutics reported a Q4 GAAP EPS of -$0.49, indicating challenges in profitability that could negatively impact investor confidence.
- Cash Reserves: As of December 31, 2025, the company held $262.9 million in cash, cash equivalents, and marketable securities, suggesting a reasonable financial buffer for planned operations in the coming years.
- Funding Plans: Contineum announced a proposed $75 million public offering aimed at enhancing financial flexibility, although its stock has dropped following a previously upsized $90 million offering, reflecting market caution regarding its financing strategy.
- Operational Funding Outlook: The company believes its cash resources are sufficient to fund operations through mid-2029, demonstrating management's confidence in future business development, yet market conditions could pose risks to its financial stability.
See More
Moderna Inc (MRNA) Projects $1.9 Billion Revenue for 2025, Shares Surge 12.8%
- Revenue Forecast Increase: At the 44th Annual J.P. Morgan Healthcare Conference, Moderna announced an expected revenue of approximately $1.9 billion for 2025, which is $100 million above the previously communicated midpoint, enhancing investor confidence and driving stock price up.
- Operating Expense Improvement: The company also lowered its projected GAAP operating expenses for 2025 by $200 million, demonstrating improved cost control capabilities that lay a solid foundation for future profitability.
- Increased Cash Balance: Moderna anticipates an end-of-year cash balance of approximately $8.1 billion, providing strong support for the company's R&D and market expansion efforts, further solidifying its market position.
- Strong Stock Performance: Following the positive news, Moderna's stock surged 12.8% to $38.20 on Tuesday, reflecting market optimism regarding its future growth potential.
See More
Contineum Therapeutics Prices Upsized Offering of 7.35M Shares at $12.25, Raising $90M
- Upsized Offering: Contineum Therapeutics has announced an upsized public offering of 7,346,938 shares of Class A common stock priced at $12.25 per share, expected to raise approximately $90 million, thereby strengthening the company's financial position to support its clinical-stage biopharmaceutical development.
- Underwriter Selection: The offering is being managed by Goldman Sachs, Leerink Partners, Stifel, RBC Capital Markets, and William Blair, reflecting market confidence in Contineum and potentially enhancing its market position in the biopharmaceutical sector.
- Additional Purchase Option: The company has granted underwriters a 30-day option to purchase up to an additional 1,102,040 shares at the same price, further enhancing financial flexibility and potentially providing additional funding for future research and development projects.
- Expected Closing Date: The offering is anticipated to close on December 15, 2025, subject to customary closing conditions, which will provide the company with much-needed capital to advance its innovative therapies targeting neuroscience, inflammation, and immunology indications.
See More
Contineum Therapeutics Prices Upsized Offering of 7.35M Shares at $12.25, Raising $90M
- Upsized Offering: Contineum Therapeutics announced the pricing of an upsized public offering of 7,346,938 shares of Class A common stock at $12.25 per share, raising approximately $90 million, which will enhance the company's financial capacity to support its R&D in biopharmaceuticals.
- Underwriter Selection: The offering is managed by Goldman Sachs, Leerink Partners, Stifel, RBC Capital Markets, and William Blair, reflecting strong market confidence in the company's future and potentially attracting more investor interest.
- Additional Purchase Option: The company granted underwriters a 30-day option to purchase an additional 1,102,040 shares at the same price, further enhancing financial flexibility and potentially providing additional funding for future R&D projects.
- Expected Closing Date: The offering is expected to close on December 15, 2025, subject to customary closing conditions, and if successful, will provide crucial funding for the company's upcoming clinical trials and product development.
See More
Contineum Therapeutics Q1 Financial Results
- Financial Performance: Contineum Therapeutics reported a Q1 GAAP EPS of -$0.39, indicating challenges in profitability that may affect investor confidence and market perception.
- Cash Reserves: As of March 31, 2026, the company held $246.3 million in cash, cash equivalents, and marketable securities, suggesting a degree of financial flexibility in the short term.
- Funding Outlook: Contineum believes its cash resources are sufficient to fund planned operations through mid-2029, reflecting confidence in future growth while highlighting current profitability concerns.
- Market Considerations: Despite the current financial struggles, Contineum must remain vigilant regarding market trends to ensure its long-term strategy can adapt to the evolving industry landscape.
See More
Contineum Therapeutics Reports Positive Phase 1b Trial Results for PIPE-791
- Trial Success: Contineum Therapeutics' PIPE-791 achieved its primary endpoint in the Phase 1b trial for chronic osteoarthritis pain and chronic low back pain, demonstrating favorable safety and tolerability, indicating its potential in non-opioid pain management.
- Trial Design Details: The study was a randomized, double-blind, placebo-controlled, 4-week crossover trial enrolling 43 patients, with 23 suffering from chronic osteoarthritis and 20 from chronic low back pain, using a daily oral dose of 10mg, ensuring the reliability of the results.
- Efficacy Assessment Results: Results indicated that patients treated with PIPE-791 showed significant improvements in pain intensity from baseline, with greater reductions compared to the placebo group, supporting further evaluation of the drug's application in chronic pain treatment.
- Positive Stock Reaction: Following the trial results announcement, CTNM's stock rose 6.48% to close at $12.82, and further increased by 9.20% in after-hours trading to $14, reflecting market optimism regarding the drug's prospects.
See More
Contineum Therapeutics Reports Q4 Earnings and Public Offering
- Earnings Report: Contineum Therapeutics reported a Q4 GAAP EPS of -$0.49, indicating challenges in profitability that could negatively impact investor confidence.
- Cash Reserves: As of December 31, 2025, the company held $262.9 million in cash, cash equivalents, and marketable securities, suggesting a reasonable financial buffer for planned operations in the coming years.
- Funding Plans: Contineum announced a proposed $75 million public offering aimed at enhancing financial flexibility, although its stock has dropped following a previously upsized $90 million offering, reflecting market caution regarding its financing strategy.
- Operational Funding Outlook: The company believes its cash resources are sufficient to fund operations through mid-2029, demonstrating management's confidence in future business development, yet market conditions could pose risks to its financial stability.
See More
Moderna Inc (MRNA) Projects $1.9 Billion Revenue for 2025, Shares Surge 12.8%
- Revenue Forecast Increase: At the 44th Annual J.P. Morgan Healthcare Conference, Moderna announced an expected revenue of approximately $1.9 billion for 2025, which is $100 million above the previously communicated midpoint, enhancing investor confidence and driving stock price up.
- Operating Expense Improvement: The company also lowered its projected GAAP operating expenses for 2025 by $200 million, demonstrating improved cost control capabilities that lay a solid foundation for future profitability.
- Increased Cash Balance: Moderna anticipates an end-of-year cash balance of approximately $8.1 billion, providing strong support for the company's R&D and market expansion efforts, further solidifying its market position.
- Strong Stock Performance: Following the positive news, Moderna's stock surged 12.8% to $38.20 on Tuesday, reflecting market optimism regarding its future growth potential.
See More
Contineum Therapeutics Prices Upsized Offering of 7.35M Shares at $12.25, Raising $90M
- Upsized Offering: Contineum Therapeutics has announced an upsized public offering of 7,346,938 shares of Class A common stock priced at $12.25 per share, expected to raise approximately $90 million, thereby strengthening the company's financial position to support its clinical-stage biopharmaceutical development.
- Underwriter Selection: The offering is being managed by Goldman Sachs, Leerink Partners, Stifel, RBC Capital Markets, and William Blair, reflecting market confidence in Contineum and potentially enhancing its market position in the biopharmaceutical sector.
- Additional Purchase Option: The company has granted underwriters a 30-day option to purchase up to an additional 1,102,040 shares at the same price, further enhancing financial flexibility and potentially providing additional funding for future research and development projects.
- Expected Closing Date: The offering is anticipated to close on December 15, 2025, subject to customary closing conditions, which will provide the company with much-needed capital to advance its innovative therapies targeting neuroscience, inflammation, and immunology indications.
See More
Contineum Therapeutics Prices Upsized Offering of 7.35M Shares at $12.25, Raising $90M
- Upsized Offering: Contineum Therapeutics announced the pricing of an upsized public offering of 7,346,938 shares of Class A common stock at $12.25 per share, raising approximately $90 million, which will enhance the company's financial capacity to support its R&D in biopharmaceuticals.
- Underwriter Selection: The offering is managed by Goldman Sachs, Leerink Partners, Stifel, RBC Capital Markets, and William Blair, reflecting strong market confidence in the company's future and potentially attracting more investor interest.
- Additional Purchase Option: The company granted underwriters a 30-day option to purchase an additional 1,102,040 shares at the same price, further enhancing financial flexibility and potentially providing additional funding for future R&D projects.
- Expected Closing Date: The offering is expected to close on December 15, 2025, subject to customary closing conditions, and if successful, will provide crucial funding for the company's upcoming clinical trials and product development.
See More
